DrugPatentWatch Database Preview
« Back to Dashboard
Summary for Patent: 5,658,760
|Title:||Heteropolymeric protein production methods|
|Abstract:||Cultured mammalian cells transfected with new vectors comprising full-length or partial .alpha. and .beta. subunit genomic DNA sequences produce significantly higher levels of dimeric glycoprotein hormone than do cells transfected with .alpha. and .beta. subunit cDNA sequences. In cases where only the cDNA clones are available, the cDNA sequences can be used in new expression vectors comprising introns or other important genomic regions from a homologous or heterologous source.|
|Inventor(s):||Kelton; Christie A. (Hopkinton, MA), Nugent; Noreen P. (Framingham, MA), Chappel; Scott C. (Boston, MA)|
|Assignee:||Genzyme Corporation (Cambridge, MA)|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for patent 5,658,760|
1. A method for accumulating, in a host cell, mRNA encoding the .alpha.-subunit of a dimeric hormone selected from the group consisting of luteinizing hormone, follicle
stimulating hormone, chorionic gonadotropin and thyroid stimulating hormone, comprising:
transforming the host cell with a vector comprising a promoter, a structural gene encoding the .alpha.-subunit, and a terminating sequence being operatively linked to permit expression of said gene by the host cell, wherein said structural gene comprises a coding region and at least one intron, wherein one intron is immediately 5' to the coding region of the .alpha.-subunit, with the proviso that the structural gene encoding the .alpha.-subunit, is not the entire genomic sequence of the gene encoding the .alpha.-subunit of bovine luteinizing hormone; and
culturing said transformed cells under conditions by which mRNA encoding said .alpha.-subunit is produced,
wherein said intron immediately 5' to the coding region of the .alpha.-subunit is spatially disposed with respect to the ATG of the coding region such that an amount of mRNA encoding said .alpha.-subunit is produced which is greater than that which can be produced under comparable conditions using a structural gene encoding the .alpha.-subunit which is the cDNA without introns.
2. A method in accordance with claim 1 wherein said structural gene includes two introns.
3. A method in accordance with claim 1 wherein said structural gene is a cDNA encoding the .alpha.-subunit.
4. A method in accordance with claim 1 wherein said intron immediately 5' to the coding region is a homologous intron.
5. A method in accordance with claim 1 wherein said intron immediately 5' to the coding region is a heterologous intron.
6. A method in accordance with claim 1, wherein said structural gene encoding the .alpha.-subunit is not the entire genomic sequence of the gene encoding said .alpha.-subunit.
7. A method in accordance with claim 1, wherein, in the structural gene encoding the .alpha.-subunit, said one intron which is immediately 5' to the coding region of the .alpha.-subunit naturally occurs at that position in the genomic sequence of the gene encoding the .alpha.-subunit of the natural dimeric protein corresponding to the dimeric protein being produced.
8. A method in accordance with claim 1, wherein said structural gene contains only a single intron.
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.